PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30206209-7 2018 ATRA treatment of MCF-7 breast cancer cells reduced p11 but not p36 transcript and protein levels, thus indicating that ATRA can regulate p11 levels independently of PML/RARalpha and p36. Tretinoin 0-4 S100 calcium binding protein A10 Homo sapiens 52-55 30621740-3 2019 The aim of this study was to investigate the potential utility of all-trans retinoid acid (ATRA), an inhibitor of the annexin A2-S100A10 signalling pathway, as a new therapeutic against serous ovarian cancer. Tretinoin 91-95 S100 calcium binding protein A10 Homo sapiens 129-136 30621740-4 2019 METHODS: In this study we determined the effects of ATRA treatment (1-5 muM) on annexin A2 and S100A10 expression, plasmin activation, and the ability of ATRA to inhibit serous ovarian cancer cell survival, motility and invasion in vitro. Tretinoin 52-56 S100 calcium binding protein A10 Homo sapiens 95-102 30621740-10 2019 In OAW28 cells, reduced cell survival following ATRA treatment was associated with a reduction of S100A10 mRNA and protein levels, S100A10 and annexin A2 membrane localization, plasmin generation, motility and invasion. Tretinoin 48-52 S100 calcium binding protein A10 Homo sapiens 98-105 30621740-10 2019 In OAW28 cells, reduced cell survival following ATRA treatment was associated with a reduction of S100A10 mRNA and protein levels, S100A10 and annexin A2 membrane localization, plasmin generation, motility and invasion. Tretinoin 48-52 S100 calcium binding protein A10 Homo sapiens 131-138 30621740-12 2019 CONCLUSIONS: These findings suggest that ATRA inhibits serous ovarian cancer proliferation and invasion via both S100A10 dependant and S100A10 independent mechanisms. Tretinoin 41-45 S100 calcium binding protein A10 Homo sapiens 113-120 30621740-12 2019 CONCLUSIONS: These findings suggest that ATRA inhibits serous ovarian cancer proliferation and invasion via both S100A10 dependant and S100A10 independent mechanisms. Tretinoin 41-45 S100 calcium binding protein A10 Homo sapiens 135-142 30206209-0 2018 Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL) . Tretinoin 56-69 S100 calcium binding protein A10 Homo sapiens 45-52 30206209-4 2018 Furthermore, treatment of the APL cell line, NB4 with all-trans retinoic acid (ATRA) causes the rapid loss of p36 and p11 protein. Tretinoin 54-77 S100 calcium binding protein A10 Homo sapiens 118-121 30206209-4 2018 Furthermore, treatment of the APL cell line, NB4 with all-trans retinoic acid (ATRA) causes the rapid loss of p36 and p11 protein. Tretinoin 79-83 S100 calcium binding protein A10 Homo sapiens 118-121 30206209-6 2018 Here, we show that the proteasomal inhibitor, lactacystin reversed the ATRA-dependent loss of p11, but did not cause an accumulation of ubiquitylated forms of p11, suggesting that ATRA promotes the proteasomal degradation of p11 in an ubiquitin-independent manner. Tretinoin 71-75 S100 calcium binding protein A10 Homo sapiens 94-97 30206209-7 2018 ATRA treatment of MCF-7 breast cancer cells reduced p11 but not p36 transcript and protein levels, thus indicating that ATRA can regulate p11 levels independently of PML/RARalpha and p36. Tretinoin 0-4 S100 calcium binding protein A10 Homo sapiens 138-141 30206209-7 2018 ATRA treatment of MCF-7 breast cancer cells reduced p11 but not p36 transcript and protein levels, thus indicating that ATRA can regulate p11 levels independently of PML/RARalpha and p36. Tretinoin 120-124 S100 calcium binding protein A10 Homo sapiens 138-141 11076800-3 2000 The addition of 10(-6) M RA resulted in reduced p11 protein levels at 4 days, with the greatest effect observed on days 6 and 7. Tretinoin 25-27 S100 calcium binding protein A10 Homo sapiens 48-51 28687976-8 2017 Treatment of zinc-induced U937/PR9 or circulating APL blasts with all-trans retinoic acid (ATRA) significantly reduced cell surface ANXA2 and S100A10 and associated reductions in IRPG and invasiveness. Tretinoin 66-89 S100 calcium binding protein A10 Homo sapiens 142-149 28687976-8 2017 Treatment of zinc-induced U937/PR9 or circulating APL blasts with all-trans retinoic acid (ATRA) significantly reduced cell surface ANXA2 and S100A10 and associated reductions in IRPG and invasiveness. Tretinoin 91-95 S100 calcium binding protein A10 Homo sapiens 142-149 21310922-4 2011 In the present study we show for the first time that the plasminogen receptor, S100A10, is present on the extracellular surface of APL cells and is rapidly down-regulated in response to all-trans retinoic acid. Tretinoin 196-209 S100 calcium binding protein A10 Homo sapiens 79-86 11076800-0 2000 Retinoic acid reduces p11 protein levels in bronchial epithelial cells by a posttranslational mechanism. Tretinoin 0-13 S100 calcium binding protein A10 Homo sapiens 22-25 11076800-7 2000 Treatment with RA reduced p11 levels in control cells and in cells transfected with a p11 expression vector, suggesting a posttranslational mechanism. Tretinoin 15-17 S100 calcium binding protein A10 Homo sapiens 26-29 11076800-7 2000 Treatment with RA reduced p11 levels in control cells and in cells transfected with a p11 expression vector, suggesting a posttranslational mechanism. Tretinoin 15-17 S100 calcium binding protein A10 Homo sapiens 86-89 11076800-8 2000 Lactacystin (10(-6) M), an inhibitor of the human 26S proteasome, blocked the decrease in p11 observed with RA treatment. Tretinoin 108-110 S100 calcium binding protein A10 Homo sapiens 90-93